| Literature DB >> 34875696 |
Madeline J Nykamp1, Charles F Zorumski1, Angela M Reiersen1, Ginger E Nicol1, John Cirrito2, Eric J Lenze1.
Abstract
Serotonin reuptake inhibitors (SRIs) are safe and widely used for a variety of indications including depressive disorders, anxiety, and chronic pain. Besides inhibiting the serotonin transporter, these medications have broad-spectrum properties in many systems. Their roles have been studied in cancer, Alzheimer's disease, and infectious processes. The COVID-19 pandemic highlighted the importance of drug repurposing of medications already in use. We conducted a narrative review of current evidence and ongoing research on drug repurposing of SRIs, with a focus on immunomodulatory, antiproliferative, and neuroprotective activity. SRIs may have clinical use as repurposed agents for a wide variety of conditions including but not limited to COVID-19, Alzheimer's disease, and neoplastic processes. Further research, particularly randomized controlled trials, will be necessary to confirm the utility of SRIs for new indications. Thieme. All rights reserved.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34875696 DOI: 10.1055/a-1686-9620
Source DB: PubMed Journal: Pharmacopsychiatry ISSN: 0176-3679 Impact factor: 5.788